Evgen Pharma PLC SFX-01 data published in peer reviewed journal (8089R)
05 Marzo 2019 - 8:00AM
UK Regulatory
TIDMEVG
RNS Number : 8089R
Evgen Pharma PLC
05 March 2019
For immediate release 5 March 2019
Evgen Pharma plc
("Evgen Pharma" or "the Company")
SFX-01 data published in Peer Reviewed Journal
Evgen's SFX-01 reduces residual disability in a model of
relapsing-remitting multiple sclerosis
Evgen Pharma (AIM: EVG), a clinical stage drug development
company focused on the treatment of cancer and neurological
conditions, is pleased to announce the publication in a
peer-reviewed scientific journal showing that its lead product,
SFX-01, reduced residual disability in a model of
relapsing-remitting multiple sclerosis ("MS").
The paper, "SFX-01 reduces residual disability after
experimental autoimmune encephalomyelitis", has been published in
the journal Multiple Sclerosis and Related Disorders and describes
the work undertaken by researchers to test the efficacy of SFX-01
in murine relapsing experimental autoimmune encephalomyelitis, a
model of MS. The data demonstrated that SFX-01 reduced residual
disability both prophylactically and after disease induction. Most
of this effect was mediated by a decrease in maximum severity of
relapses and improved recovery during follow-up. Histological
examination of the spinal cord was consistent with the clinical
findings, with improvement in demyelination and the number of
apoptotic cells, but not inflammatory cell infiltration.
The publication follows Evgen's presentation of its preclinical
study data of SFX-01 in various models of the relapsing remitting
form of multiple sclerosis at the 32nd Congress of the European
Committee for Treatment and Research in Multiple Sclerosis
(ECTRIMS) .
The paper can be viewed at:
https://www.msard-journal.com/article/S2211-0348(19)30104-X/fulltext
(Ian Galea et al; SFX-01 reduces residual disability after
experimental autoimmune encephalomyelitis, Multiple Sclerosis and
Related Disorders, 2019).
Steve Franklin, CEO of Evgen Pharma, commented:
"The leading product in MS treatment generates revenues of
several billion dollars per annum despite an adverse side effect
profile. There is an attractive opportunity for oral
disease-modifying agents with comparable or better efficacy and an
improved side-effect profile."
Ian Galea, Associate Professor in Experimental Neurology, who
leads the Southampton Clinical and Experimental Neurology Team
(http://go.soton.ac.uk/6ya) at the University of Southampton,
said:
"We remain excited by the potential of SFX-01 for relapsing
remitting multiple sclerosis, and also the secondary progressive
form of the disease. On the back of this data, we will work with
Evgen to explore all sources of charitable, grant and commercial
funding to ensure that this opportunity is progressed."
Enquiries:
Evgen Pharma plc c/o +44 (0) 20 7466 5000
Dr Stephen Franklin, CEO
Richard Moulson, CFO
www.evgen.com
finnCap
Geoff Nash, Teddy Whiley (Corporate
Finance)
Alice Lane, Manasa Patil (ECM)
www.finncap.com +44 (0) 20 7220 0500
WG Partners LLP
Nigel Barnes, Claes Spång +44 (0) 20 3705 9330
Buchanan
Mark Court, Sophie Wills, Tilly
Abraham
evgen@buchanan.uk.com +44 (0) 20 7466 5000
Notes for editors:
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company whose
lead programmes are in breast cancer and subarachnoid haemorrhage,
a type of stroke. The Company's core technology is Sulforadex(R), a
method for synthesising and stabilising the naturally occurring
compound sulforaphane and novel proprietary analogues based on
sulforaphane. The lead product, SFX-01, is a patented composition
of synthetic sulforaphane and alpha-cyclodextrin.
The Group commenced operations in January 2008 and has its
headquarters at The Colony, Wilmslow, Cheshire, and its registered
office is at the Liverpool Science Park, Liverpool. It joined the
AIM market of the London Stock Exchange in October 2015 and trades
under the ticker symbol EVG.
For further information, please visit: www.evgen.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCCKQDPCBKDKNK
(END) Dow Jones Newswires
March 05, 2019 02:00 ET (07:00 GMT)
Grafico Azioni Evgen Pharma (LSE:EVG)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Evgen Pharma (LSE:EVG)
Storico
Da Lug 2023 a Lug 2024